Days after finally getting the FDA’s go-ahead to resume the stop-and-start development of its lead candidate, Geron has signed a deal to cut Johnson & Johnson in on the process, putting the biotech in line for as much as $935 million if all goes according to plan.

…read more

Source: J&J bets up to $935M that Geron’s drug can shake a checkered past


0 No comments